Last reviewed · How we verify
ZDV+3TC+LPV/r
This combination inhibits HIV reverse transcriptase and protease to suppress viral replication.
This combination inhibits HIV reverse transcriptase and protease to suppress viral replication. Used for HIV-1 infection in pediatric and adolescent patients, Prevention of mother-to-child transmission of HIV.
At a glance
| Generic name | ZDV+3TC+LPV/r |
|---|---|
| Also known as | Zidovudine, Retrovir, Lamivudine, Epivir, Lopinavir/ritonavir |
| Sponsor | International Maternal Pediatric Adolescent AIDS Clinical Trials Group |
| Drug class | Antiretroviral combination therapy (NRTI + PI) |
| Target | HIV reverse transcriptase; HIV protease |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Virology |
| Phase | FDA-approved |
Mechanism of action
ZDV (zidovudine) and 3TC (lamivudine) are nucleoside reverse transcriptase inhibitors that block HIV reverse transcriptase, while LPV/r (lopinavir/ritonavir) is a protease inhibitor that prevents HIV protease from cleaving viral polyproteins. Together, they target multiple steps of the HIV replication cycle to reduce viral load and preserve immune function.
Approved indications
- HIV-1 infection in pediatric and adolescent patients
- Prevention of mother-to-child transmission of HIV
Common side effects
- Diarrhea
- Nausea
- Lipid abnormalities
- Hepatotoxicity
- Pancreatitis
- Mitochondrial toxicity
Key clinical trials
- Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV (PHASE2, PHASE3)
- A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments (PHASE4)
- Early Infant HIV Treatment in Botswana (PHASE2, PHASE3)
- A Prospective Cohort of Children With HIV Infection
- Antiretroviral Regime for Viral Eradication in Newborns (PHASE4)
- Anti-HIV Drug Regimens and Treatment-Switching Guidelines in HIV Infected Children (PHASE2, PHASE3)
- Cyclosporine A in Combination With Abacavir Sulfate, Lamivudine, and Zidovudine and Lopinavir/Ritonavir in HIV (PHASE2)
- Comparison of Three Anti-HIV Regimens to Prevent Nevirapine Resistance in Women Who Take Nevirapine During Pregnancy (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ZDV+3TC+LPV/r CI brief — competitive landscape report
- ZDV+3TC+LPV/r updates RSS · CI watch RSS
- International Maternal Pediatric Adolescent AIDS Clinical Trials Group portfolio CI